ALISPORIVIR DESTINE AU TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE L'HEPATITE C

• 收藏
• 分享

专利权人:

NOVARTIS AG

发明人:

AVILA, CLAUDIO

申请号：

CA2850052

公开号：

CA2850052A1

申请日:

2012.09.25

申请国别(地区):

CA

年份:

2013

代理人:

摘要：

The invention concerns the use of alisporivir (= Debio-025 or DEB025) in the treatment of Hepatitis C virus infection genotype 1 infected African American patient. Alisporivir is to be administered in an amount of about 400 to about 600 mg twice per day, preferably in combination with other antiviral agents. In a preferred embodiment, the following dosage regimen is administered : pegylated interferon alfa 2a (PEGASYS) at a dose of 180 ug subcutaneously once weekly for 24 or 48 weeks in combination with ribavirin (RBV or COPEGUS) administered in an oral dosage of 800/1200 mg daily (weight based) for 24 or 48 weeks and 400 mg alisporivir (DEB025) orally twice daily for 24 or 48 weeks.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/